论文部分内容阅读
目的观察促红细胞生成素(EPO)治疗早产儿贫血的治疗效果和安全性。方法随机选取来我院进行治疗的早产儿104例,将其随机均分为A、B组各52例,分别进行常规治疗(A组)和在常规治疗的基础上再注射促红细胞生成素(B组),然后观察治疗前后红细胞积压(HCT)、Hb、网织红细胞计数(Ret)三个指标的变化情况。结果治疗后,2组的3个指标均有改善,且B组的各项指标的变化均要高于A组差异有统计学意义(P<0.05);B组的输血率15.3%和不良反应发生率要远远低于A组的输血率48.1%,差异有统计学意义(P<0.05);2组均未观察到视网膜并发病。结论注射EPO治疗早产儿贫血能够改善骨髓造血功能,减少输血次数和相应的不良反应,EPO的治疗时安全有效的,值得进一步的推广。
Objective To observe the therapeutic effect and safety of erythropoietin (EPO) on anemia in premature infants. Methods A total of 104 preterm infants randomly selected from our hospital for treatment were randomly divided into A group and B group, with 52 cases in each group. The patients in group A received routine injection of erythropoietin Group B). The change of HCT, Hb and Ret counts before and after treatment were observed. Results After treatment, the three indexes improved in both groups, and the changes of each index in group B were higher than those in group A (P <0.05). The blood transfusion rate in group B was 15.3% and the adverse reactions The incidence was much lower than that in group A (48.1%), the difference was statistically significant (P <0.05). No retinopathy was observed in the two groups. Conclusion The injection of EPO in the treatment of premature infant anemia can improve the hematopoietic function of bone marrow, reduce the number of transfusions and the corresponding adverse reactions. EPO is safe and effective in the treatment and is worth further promotion.